Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: IMO Schwartz stock sales may be the key that unravels this conundrum
"Because there is a Markman ruling in that District that is completely in our favor.. and the 'reason' why/if there was a settlement for nickels on the dollar is sealed under the CC, and the T3 will not/should never know what it is.. Their lawyers can take a shot or settle.."
Did anyone think of this point?
The lawyers of the T3 and all the other companies, which are currently in license negotiations, would obviously point to the PTSC numbers and tell TPL 'No, we are not paying more. We look at the recent 10-Q of your partner PTSC, where license fees from the J3 and some big names seem to be quite small - AND we read the shareholder letter from their CEO, where he says, every transaction has been listed. Why should we pay the money, you are demanding?'
If the situation was like most assume (that there is nothing more to come from the settlement), then TPL would be in an incredible weak position to negotiate with the "waiting" 400 companies.
Quite unbelievable for me - because it would in fact destroy the complete value of the MMP, not only for PTSC, but for TPL, too! And they have a lot more monthly expenses than PTSC has...
Thus IMO TPL has to have a strong answer to these lawyers in order to defend the money they demand.
Getting back in lurking mode: GLTA
Share
New Message
Please login to post a reply